Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases. A systematic review and meta-analysis. JAMA Dermatol 2020:20 de mayo. [Ref.ID 103629]

Anónimo. Hydroclorothiazide: cancers de la peau. Prescrire 2018;38:347. [Ref.ID 102655]

Anónimo. Fingolimod (Gilenya): nuevas contraindicaciones de uso en pacientes con patología cardiaca subyacente y recomendaciones de revisiones dermatológicas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:6 de noviembre. [Ref.ID 102124]

Anónimo. Pembrolizumb et mélanomes métastasés ou inopérables. Prescrire 2016;36:889-91. [Ref.ID 101003]

Anónimo. Sonidégib et carcinome basocellulaire étendu. Prescrire 2016;36:652-4. [Ref.ID 100818]

Anónimo. Nivolumab. Prescrire 2016;36:500-1. [Ref.ID 100553]

Anónimo. Tramétinib. Prescrire 2016;36:490-1. [Ref.ID 100549]

de Maleissye M-F, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 2016;375:296-7. [Ref.ID 100503]

Anónimo. NICE rejects melanoma combination therapy as too expensive. DIA Daily 2016:1. [Ref.ID 100431]

Raaschou P, Simard JF, Hagelberg CA, Askling J, for the ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ 2016;352:i262. [Ref.ID 100038]

Assassi S. Rheumatoid arthritis, TNF inhibitors, and non-melanoma skin cancer. BMJ 2016;352:i472. [Ref.ID 100032]

Anónimo. Nivolumab (Opdivo) plus ipilimumab (Yervoy) for metastatic melanoma. Med Lett Drugs Ther 2015;57:168. [Ref.ID 99691]

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, Gare C, Jouary T, Hauschild A, Grob J-J, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015;386:444-51. [Ref.ID 99482]

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus SW, Ribas S, KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32. [Ref.ID 99312]

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Gamo H, Ingvar C, Stattin P. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 2015;313:2449-55. [Ref.ID 99307]

Postow MA, Chesney J, Pavick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-17. [Ref.ID 99140]

Anónimo. Ipilimumab et mélanome métastasé ou inopérable. Prescrire 2015;35:95. [Ref.ID 98911]

Anónimo. Vémurafénib avec plus de recul. Mélanome métastasé: quelques mois de survie en plus, mais beaucoup d'effets indésirables. Prescrire 2014;34:893-4. [Ref.ID 98469]

Anónimo. Dabrafénib. Mélanome métastasé: me-too du vémurafénib. Prescrire 2014;34:889-92. [Ref.ID 98468]

Anónimo. FDA approves new immunotherapy for melanoma. DIA Daily 2014:5 de septiembre. [Ref.ID 97863]